Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Cardiff Oncology reports Q1 EPS (14c), consensus (15c) » 17:01
05/06/21
05/06
17:01
05/06/21
17:01
CRDF

Cardiff Oncology

$9.04 /

-0.985 (-9.83%)

Reports Q1 revenue $72K,…

Reports Q1 revenue $72K, consensus $150K. "We are off to a strong start in 2021 thanks in large part to our successful financing late last year, which has allowed us to advance our clinical development programs, more fully leverage onvansertib combination trials across multiple cancer indications, and work towards strengthening company leadership," said CEO Mark Erlander.

ShowHide Related Items >><<
CRDF Cardiff Oncology
$9.04 /

-0.985 (-9.83%)

CRDF Cardiff Oncology
$9.04 /

-0.985 (-9.83%)

02/11/21 Piper Sandler
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
CRDF Cardiff Oncology
$9.04 /

-0.985 (-9.83%)

  • 30
    Sep
CRDF Cardiff Oncology
$9.04 /

-0.985 (-9.83%)

Over a week ago
Conference/Events
Cardiff Oncology to hold a Key Opinion Leader conference call » 10:25
04/12/21
04/12
10:25
04/12/21
10:25
CRDF

Cardiff Oncology

$9.43 /

+0.18 (+1.95%)

CEO Erlander, along with…

CEO Erlander, along with KOLs Daniel Ahn, D.O. (Mayo Clinic Arizona) and Manish Sharma, MD (START Midwest) hold a conference call to discuss Onvansertib for treatment of KRAS-Mutated Metastatic Colorectal Cancer to be held on April 12 at 11 am. Webcast Link

ShowHide Related Items >><<
CRDF Cardiff Oncology
$9.43 /

+0.18 (+1.95%)

CRDF Cardiff Oncology
$9.43 /

+0.18 (+1.95%)

02/11/21 Piper Sandler
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
CRDF Cardiff Oncology
$9.43 /

+0.18 (+1.95%)

  • 30
    Sep
CRDF Cardiff Oncology
$9.43 /

+0.18 (+1.95%)

Hot Stocks
Cardiff Oncology announces data from onvansertib trial » 06:06
04/12/21
04/12
06:06
04/12/21
06:06
CRDF

Cardiff Oncology

$9.25 /

-0.2 (-2.12%)

Cardiff Oncology…

Cardiff Oncology announced data from its ongoing Phase 1b/2 trial that demonstrate the patient response to treatment with onvansertib and progression-free survival when combined with standard-of-care therapy in second line KRAS-mutated metastatic colorectal cancer, or mCRC. Patients enrolled in the ongoing Phase 1b/2 trial receive onvansertib in combination with standard-of-care FOLFIRI and Avastin. The overall response rate, or ORR in the trial is 39% to-date, and onvansertib in combination with FOLFIRI/bevacizumab has been well tolerated with no major or unexpected toxicities attributed to onvansertib. The median progression free survival, or mPFS, of evaluable patients is 9.4 months. This represents an increase over the mPFS observed in a systematic literature-based analysis of second line mCRC clinical trial data from 23 randomized trials including a total of approximately 10,800 patients and the 5.7-month mPFS observed in the pivotal trial that supported the regulatory approval of FOLFIRI plus bevacizumab in second line mCRC. Overall, seven of 18 evaluable patients achieved a partial response, or PR; four patients had a confirmed PR with one patient going on to curative surgery; one patient with a non-confirmed PR went off study following PR prior to confirmatory scan due to a treatment-unrelated adverse event; two patients with non-confirmed PRs await results from confirmatory scans. Evaluable patients have a mPFS of 9.4 months. Seven patients remain on treatment to-date. Clinical responses were observed across different KRAS mutations, including the three most common in colorectal cancer. The greatest decreases in plasma KRAS mutant allelic frequency, or MAF, after one cycle of treatment were observed in patients achieving a PR. All seven patients with a PR had a greater than 75% decrease in KRAS MAF after one cycle of treatment. Onvansertib in combination with FOLFIRI/bevacizumab has been well tolerated with no major or unexpected toxicities attributed to onvansertib.

ShowHide Related Items >><<
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

02/11/21 Piper Sandler
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

  • 30
    Sep
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

Conference/Events
Cardiff Oncology to hold a Key Opinion Leader conference call » 04:55
04/12/21
04/12
04:55
04/12/21
04:55
CRDF

Cardiff Oncology

$9.25 /

-0.2 (-2.12%)

CEO Erlander, along with…

CEO Erlander, along with KOLs Daniel Ahn, D.O. (Mayo Clinic Arizona) and Manish Sharma, MD (START Midwest) hold a conference call to discuss Onvansertib for treatment of KRAS-Mutated Metastatic Colorectal Cancer to be held on April 12 at 11 am. Webcast Link

ShowHide Related Items >><<
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

02/11/21 Piper Sandler
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

  • 30
    Sep
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

Hot Stocks
Cardiff presents gene signature analyses related to Phase 2 onvansertib trial » 16:43
04/11/21
04/11
16:43
04/11/21
16:43
CRDF

Cardiff Oncology

$9.25 /

-0.2 (-2.12%)

Cardiff Oncology, in…

Cardiff Oncology, in collaboration with scientists in the Center for Precision Cancer Medicine at the Massachusetts Institute of Technology, announced that new gene signature and mechanistic analyses related to its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer were featured in a virtual oral poster presentation at the American Association for Cancer Research Annual Meeting 2021. Analyses presented in the poster suggest that the androgen receptor signaling inhibitor abiraterone sensitizes certain prostate cancer cells to onvansertib by upregulating a set of mitosis related genes and disrupting mitotic spindle orientation. These results are consistent with previous findings showing that onvansertib and abiraterone synergize in an androgen receptor-independent manner in-vitro and in-vivo. Highlights from the AACR presentation include: Inhibition of polo-like kinase 1 sensitizes CRPC cells to abiraterone, but not the ARSi enzalutamide, indicating that abiraterone and PLK1 inhibitors synergize in an AR-independent manner; In vitro experiments and RNA sequencing analyses indicate that abiraterone's AR-independent effects include the disruption of mitotic spindle orientation and the induction of a mitosis related gene signature; Data suggest that the identified mitosis related gene signature may be predictive of patient response to onvansertib-abiraterone combination therapy, a hypothesis that is being further assessed in an ongoing Phase 2 trial evaluating the all-oral regimen of onvansertib, abiraterone and prednisone in mCRPC patients; The identified mitosis related gene signature was found to be significantly enriched in the basal molecular subtype of prostate cancer.

ShowHide Related Items >><<
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

02/11/21 Piper Sandler
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

  • 30
    Sep
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

Hot Stocks
Cardiff presents findings from EAP of onvansertib in KRAS-mutated mCRC » 16:39
04/11/21
04/11
16:39
04/11/21
16:39
CRDF

Cardiff Oncology

$9.25 /

-0.2 (-2.12%)

Cardiff Oncology…

Cardiff Oncology announced observations from its Expanded Access Program of onvansertib in KRAS-mutated metastatic colorectal cancer, featured in a virtual oral poster presentation at the American Association for Cancer Research Annual Meeting 2021. The company's investigational drug, onvansertib, a first-in-class, third-generation Polo-like Kinase 1 inhibitor, is being evaluated in combination with standard-of-care chemotherapy and targeted therapeutics. Cardiff Oncology's EAP has enrolled participants who failed or progressed on multiple lines of standard-of-care treatment and uses the same combination regimen and dosing schedule as the company's ongoing Phase 1b/2 mCRC clinical trial. The median progression free survival of evaluable participants in the EAP is 5.6 months to-date, which represents an increase over the 2-3 months mPFS of historical controls1. 62.5% of participants had a greater than 50% decrease in KRAS MAF after one cycle of treatment and continue to show a durable response, having not yet reached the mPFS. Onvansertib has been well tolerated with no serious adverse events reported as of the AACR cutoff date.

ShowHide Related Items >><<
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

02/11/21 Piper Sandler
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

  • 30
    Sep
CRDF Cardiff Oncology
$9.25 /

-0.2 (-2.12%)

Over a month ago
Conference/Events
Cardiff Oncology to hold a Key Opinion Leader conference call » 14:44
04/06/21
04/06
14:44
04/06/21
14:44
CRDF

Cardiff Oncology

$10.00 /

+0.22 (+2.25%)

CEO Erlander, along with…

CEO Erlander, along with KOLs Daniel Ahn, D.O. (Mayo Clinic Arizona) and Manish Sharma, MD (START Midwest) hold a conference call to discuss Onvansertib for treatment of KRAS-Mutated Metastatic Colorectal Cancer to be held on April 12 at 11 am. Webcast Link

ShowHide Related Items >><<
CRDF Cardiff Oncology
$10.00 /

+0.22 (+2.25%)

CRDF Cardiff Oncology
$10.00 /

+0.22 (+2.25%)

02/11/21 Piper Sandler
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
CRDF Cardiff Oncology
$10.00 /

+0.22 (+2.25%)

  • 30
    Sep
CRDF Cardiff Oncology
$10.00 /

+0.22 (+2.25%)

Syndicate
Cardiff Oncology files automatic mixed securities shelf  16:12
03/12/21
03/12
16:12
03/12/21
16:12
CRDF

Cardiff Oncology

$10.88 /

+0.2 (+1.87%)

 
ShowHide Related Items >><<
CRDF Cardiff Oncology
$10.88 /

+0.2 (+1.87%)

CRDF Cardiff Oncology
$10.88 /

+0.2 (+1.87%)

02/11/21 Piper Sandler
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
CRDF Cardiff Oncology
$10.88 /

+0.2 (+1.87%)

  • 30
    Sep
CRDF Cardiff Oncology
$10.88 /

+0.2 (+1.87%)

CRDF Cardiff Oncology
$10.88 /

+0.2 (+1.87%)

Earnings
Cardiff Oncology reports Q4 EPS (19c), consensus (14c) » 17:04
02/25/21
02/25
17:04
02/25/21
17:04
CRDF

Cardiff Oncology

$9.78 /

-0.52 (-5.05%)

Reports Q4 revenue $119K,…

Reports Q4 revenue $119K, consensus $30K. "Over the last several months we achieved key clinical milestones, which provided the momentum for our successful raise of over $100M. Together, these events have enabled us to accelerate the execution of our clinical programs and expand our pipeline to other relevant cancer indications," said CEO Mark Erlander. "(...) Looking ahead, the progress we've made across our clinical programs leaves us poised to achieve a steady cadence of catalysts throughout 2021 and beyond as we continue to advance onvansertib's development."

ShowHide Related Items >><<
CRDF Cardiff Oncology
$9.78 /

-0.52 (-5.05%)

CRDF Cardiff Oncology
$9.78 /

-0.52 (-5.05%)

02/11/21 Piper Sandler
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
CRDF Cardiff Oncology
$9.78 /

-0.52 (-5.05%)

  • 30
    Sep
CRDF Cardiff Oncology
$9.78 /

-0.52 (-5.05%)

CRDF Cardiff Oncology
$9.78 /

-0.52 (-5.05%)

Recommendations
Piper says Cardiff Oncology mCRPC opportunity 'more interesting' after data » 10:19
02/11/21
02/11
10:19
02/11/21
10:19
CRDF

Cardiff Oncology

$13.35 /

+0.29 (+2.22%)

After Cardiff Oncology…

After Cardiff Oncology provided an update to the ongoing Phase 2 study of onvansertib + abiraterone in metastatic castrate-resistant prostate cancer, or mCRPC, at the ASCO-GU meeting, Piper Sandler analyst Joseph Catanzaro said he views the indication of a dose response as providing a positive signal that onvansertib is contributing to the clinical benefit being observed. While he notes that any future revenues from onvansertib in mCRPC are currently excluded from his model, he thinks "today's update makes this opportunity incrementally more interesting" and he keeps an Overweight rating on Cardiff shares with a $25 price target.

ShowHide Related Items >><<
CRDF Cardiff Oncology
$13.35 /

+0.29 (+2.22%)

CRDF Cardiff Oncology
$13.35 /

+0.29 (+2.22%)

10/22/20
Fly Intel: Top five analyst initiations
10/22/20 H.C. Wainwright
Cardiff Oncology initiated with a Buy at H.C. Wainwright
10/21/20 Maxim
Cardiff Oncology price target raised to $20 from $14 at Maxim
10/08/20
Fly Intel: Top five analyst initiations
CRDF Cardiff Oncology
$13.35 /

+0.29 (+2.22%)

  • 30
    Sep
CRDF Cardiff Oncology
$13.35 /

+0.29 (+2.22%)

CRDF Cardiff Oncology
$13.35 /

+0.29 (+2.22%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.